Drug Type CRISPR/Cas9, AAV based gene therapy |
Synonyms COG 101, COG101 |
Target |
Action antagonists |
Mechanism 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anxiety Disorders | Preclinical | United States | 14 May 2024 | |
Memory Disorders | Preclinical | United States | 14 May 2024 |